Menu
Synthetic Biology Engineer
Three components - Automation Resistance, Structural Moat, and Demand - add up to 60.
Federal labor data does not isolate synthetic-biology engineering as its own occupation. This score uses the broader Bioengineers and Biomedical Engineers occupation, with synthetic-biology lab, scale-up, biosafety, and commercialization details layered into the explanation.
AI reaches design, literature, protocol, and data-analysis work, but noisy biology, lab validation, biosafety, scale-up, and regulated production keep the human loop important. Exposure is real, not decisive. Lab validation is the boundary software cannot cross on its own.
Observed exposure for the broader bioengineering occupation is 13.28%, and vulnerability modeling shows meaningful pressure on analysis-heavy tasks. Synthetic biology still requires lab validation, troubleshooting, biosafety judgment, and scale-up decisions that cannot be trusted to software alone.
AI is highly useful for sequence ideas, literature scans, protocol drafts, data analysis, experiment planning, and documentation. Skilled workers can capture some of that lift when they understand both the biology and the engineering constraints, though employers and platform tools also absorb part of the productivity gain.
The protective layer is technical depth, wet-lab practice, regulated context, and manufacturing know-how. The role has lab exposure and quality rules, but no broad occupational license. Regulated manufacturing raises barriers in some lanes, but not all.
Synthetic-biology engineers may work in labs, cleanrooms, pilot plants, or biomanufacturing spaces, but many design and analysis tasks are screen-heavy. The setting is mixed: more physical than a pure software role, less physically protected than a field trade.
Biosafety, FDA-facing development, good manufacturing practice, and product regulation matter, but they regulate the work and the product more than they license the worker. A synthetic-biology engineer usually does not hold a protected occupational license.
Lab automation and cloud-lab tools can handle structured pipetting, screening, and measurement tasks, but biology remains noisy and context-dependent. The robotics risk is real in routine lab execution; it is lower in assay interpretation, troubleshooting, scale-up, and regulated decision-making.
The usual path starts with bioengineering, biomedical engineering, biology plus engineering, or computational biology training. Research-heavy roles often favor graduate study, while manufacturing roles may value process and quality experience. That creates real credential depth without a universal license.
Demand is real across therapeutics, diagnostics, agriculture, materials, biofoundries, and biomanufacturing, but the labor market is still small, commercialization-sensitive, and uneven by lane. Commercial proof and repeat hiring decide the band, not research excitement alone for students entering now.
The broader bioengineering occupation has about 22,200 jobs, about 5.2% projected growth, and about 1,300 annual openings. That is a real labor market, but still small compared with broad engineering, healthcare, or trades occupations.
Synthetic-biology demand is supported by real work in therapeutics, diagnostics, bioindustrial manufacturing, biofoundries, and platform biology. The evidence is mixed because public labor data does not separate this lane and because hiring depends on commercialization, funding, and regulatory progress.
The work is vulnerable to funding cycles, platform shakeouts, failed products, and regulatory delays. At the same time, validated biology, process scale-up, quality systems, and manufacturing transfer do not disappear when design tools improve.
The score would weaken if cloud labs and automation made routine design-build-test cycles cheap, reliable, and less staff-heavy across normal employers. The warning sign is fewer entry-level lab engineering seats, not faster experiment planning. Employers would need fewer people to run ordinary cycles.
The score would strengthen if therapeutics, diagnostics, agriculture, materials, and bioindustrial manufacturing created steadier production and quality roles. The trigger is repeat hiring around scale-up and regulated operations, not one-time research funding. That would make hiring less dependent on discovery funding.
The score would fall if venture funding, public research support, or product approvals slowed enough to cut platform and early-stage hiring. Manufacturing and quality roles would hold up better than discovery-only roles. Early-career discovery roles would feel the pressure first.